The evidence on erectile dysfunction (ED) is less clear than it is for common GLP-1 side effects such as nausea. The studies examined different drugs and groups of men. They also measured different things, from diagnoses in medical records to scores on an erectile function questionnaire.
What did researchers find in men with type 2 diabetes?
A U.S. medical record study compared 4,910 men who started a GLP-1 drug with 5,524 who started a DPP-4 inhibitor. ED was recorded at 35.2 versus 28.0 cases per 1,000 person-years. The weighted hazard ratio was 1.26 (95% CI 1.08 to 1.46) [1].
The authors also checked their method against outcomes the drugs would be unlikely to cause, a technique called negative control calibration. After calibration, the association was weaker and no longer statistically significant. Because the study relied on diagnosis codes, differences in how often ED was discussed or documented could affect the results.
What did a randomized trial measure?
An exploratory analysis of the REWIND trial included 3,725 men with type 2 diabetes who completed an erectile function questionnaire at baseline and at least once in follow-up. It found 21.3 first postrandomization cases of moderate or severe ED per 100 person-years with dulaglutide versus 22.0 with placebo (HR 0.92, 95% CI 0.85 to 0.99) [2]. The finding applies to dulaglutide in that trial population. It cannot establish the effect of semaglutide or tirzepatide.
What about semaglutide for weight loss?
A separate U.S. electronic record study matched 3,094 men aged 18 to 50 with obesity and no diabetes who were prescribed semaglutide to 3,094 who were not. It counted an ED diagnosis or a prescription for a PDE5 inhibitor, a type of ED medication. The combined outcome occurred in 1.47% versus 0.32% (RR 4.5, 95% CI 2.3 to 9.0) [3]. A prescription record cannot establish whether someone took semaglutide, and the study cannot show whether it caused the difference.
If you notice a change in erectile function after starting treatment, tell your prescriber when it began. The timing is one piece of information a clinician can use to evaluate it.